Terns Pharmaceuticals : Corporate Presentation June 2025

Published: 2025-06-06 08:57:20 ET TERN

Published on 06/06/2025 at 08:57

NASDAQ: TERN

June 2025

Moving science forward from validated to revolutionary, creating medicines that have a valuable, enduring impact on human health

3

2

clinically validated

molecules

2

large indications with

unmet need

2

significant clinical

readouts in 4Q25

TERN-701

Allosteric BCR-ABL inhibitor for CML

TERN-601

Oral, small molecule GLP-1RA for obesity

Potential best-in-class treatment in a $5B+ CML market

High probability of clinical success & clear path to 1L market

Differentiated Ph1

obesity dataset

Distinct drug properties may enable competitive weight loss + superior tolerability

Early clinical data supports differentiated profile

Upcoming 4Q25 data with read through to registrational endpoint

Oral, small molecule is easy to manufacture and scale

Ph2 designed to support differentiation thesis; upcoming 12-week data in 4Q25

Cash of $334M1 provides runway to multiple data catalysts and into 2028

Balance Sheet

CML: chronic myeloid leukemia; 1L: frontline setting; GLP-1RA: glucagon-like peptide-1 receptor agonist

1. As of March 31, 2025; includes marketable securities 4

PROGRAM

MECHANISM

INDICATION

PRECLINICAL

EARLY-STAGE CLINICAL DEVELOPMENT

LATE-STAGE CLINICAL DEVELOPMENT

STATUS / NEXT ANTICIPATED

MILESTONE

TERN-7011

Allosteric BCR-ABL Inhibitor

CML

Phase 1

Anticipated registrational trial following Ph 1 trial

Ph1 CARDINAL ongoing Positive early data in Dec '24; Initiated does expansion in 2Q25; additional efficacy data in 4Q25

Phase 2

Positive top-line Ph1 data (28-day PoC) Sept '24 Phase 2 underway, initial 12-week data in 4Q25

Phase 2 Ready

GIPR Antagonist Lead Opt.

Positive Ph2a NASH data Preclinical data in combo with GLP-1 (enhanced and higher quality weight)

GIPR antagonist lead

optimization underway

5

1) In 2020, Terns granted Hansoh exclusive option to license TERN-701 in mainland China, Taiwan, Hong Kong and Macau.

CML: chronic myeloid leukemia, GLP-1R: glucagon-like peptide-1 receptor, THR-β: thyroid hormone receptor beta, GIPR: glucose-dependent insulinotropic polypeptide receptor, opt: optimization, PoC: proof of concept

Disclaimer

Terns Pharmaceuticals Inc. published this content on June 06, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 06, 2025 at 12:56 UTC.